“As the regulatory environment for life sciences companies continues to become even more intricate to navigate, Scott’s particular focus on the regulation of drugs and biologics, from pharmaceutical lifecycle management to labeling and approval issues, will perfectly complement our multidisciplinary practice,” said Mitchell Bloom, Chair of Goodwin’s Life Sciences Practice. “Having a recognized leader in FDA regulation join our team strengthens our capabilities and international platform. We are delighted that Scott has chosen to join Goodwin.”
With more than 25 years of experience, Lassman focuses on providing life cycle support to biotechnology, pharmaceutical and medical technology companies at all stages of development. He has extensive experience counseling senior management on navigating the FDA’s complex administrative processes and structures, including its dispute resolution and Citizen Petition processes, and has successfully obtained preliminary and permanent injunctive relief from the FDA in drug and device cases. Lassman routinely provides strategic advice on product approval and lifecycle management issues, including the Hatch-Waxman Act and biosimilars law, and also advises clients on corporate, licensing and intellectual property issues.
Lassman joins Goodwin from Kleinfeld, Kaplan & Becker, where he was a partner. He earned his J.D. from the University of Virginia School of Law, his M.A. from the University of Texas at Austin and his B.A. (cum laude) from Yale University. Lassman is a member of the Maryland and District of Columbia Bar Associations.
Lassman can be reached at email@example.com or (202) 346-4134.
Goodwin’s Life Sciences Practice is among the leading practices in the United States, with more than 100 experienced life sciences lawyers. Its full-service team serves all legal needs of life sciences clients from corporate and partnering to intellectual property, regulatory and litigation. Goodwin was named U.S. News-Best Lawyers’ “Law Firm of the Year” in Biotechnology Law for three consecutive years (2013-2015). Clients include more than 400 private and public life sciences companies and their investors, from start-ups and Fortune 100 corporations to venture capital funds and investment banks.